GLP1 Clinics News Desk
News Desk
The GLP1 Clinics News Desk covers breaking developments in the GLP-1 medication space, including regulatory changes, new clinical data, manufacturer announcements, and policy updates that impact patient access to weight loss treatments.
Areas of Expertise
Articles by GLP1 Clinics News Desk
Medicare Launches $50 GLP-1 Coverage Starting July as Historic Access Barrier Falls
CMS will provide Medicare beneficiaries access to Wegovy, Zepbound, and Foundayo for $50/month starting July 1, 2026, marking the first time Medicare covers weight loss medications.
FDA Sends 30 Warning Letters to Telehealth Companies Over Misleading GLP-1 Claims
The FDA cracked down on telehealth companies making false claims about compounded GLP-1 alternatives, sending 30 warning letters in its biggest enforcement action yet.
Trump Admin Delays Medicare GLP-1 Coverage After Insurers Balk at Program
The BALANCE Model for Medicare GLP-1 coverage is indefinitely postponed after failing to meet 80% insurer participation threshold, though Bridge program extends through 2027.
FDA Requests Safety Studies for Foundayo Despite Recent Approval
Just days after approving Foundayo, the FDA is asking Eli Lilly for additional data on potential heart, liver, and thyroid cancer risks.
AI-Powered GLP-1 Telehealth Giant MEDVi Faces FDA Warnings and Lawsuits
MEDVi, profiled by NYT as an AI-powered $1.8B telehealth success story, faces FDA warnings, RICO lawsuits over compounded GLP-1s, and major data breach affecting 1.6M patients.
FDA Safety Data Reveals Distinct Risk Profiles Across Different GLP-1 Drugs
New analysis of 137,000 FDA adverse event reports shows each GLP-1 medication has unique safety patterns, with semaglutide linked to more psychiatric events and concerning findings for women.
FDA Approves Foundayo: Eli Lilly's GLP-1 Pill with No Food Restrictions
Eli Lilly's Foundayo becomes the second GLP-1 pill approved for weight loss, offering unique flexibility with no food or water restrictions and $149 starting price.
FDA Approves Wegovy HD: First High-Dose GLP-1 Delivers Record 20.7% Weight Loss
FDA fast-tracked approval of Wegovy HD (7.2 mg semaglutide) under new priority program, achieving highest weight loss on record for any GLP-1 injection.
New Protein Research Redefines Muscle Preservation on GLP-1 Medications
Major studies reveal people on GLP-1s need 1.5-2.3g protein per kg of lean body mass daily to prevent muscle loss, with new 'protein pacing' strategies emerging as game-changers.
CMS Launches BALANCE Model to Expand GLP-1 Access in Medicare and Medicaid
The Trump administration's new BALANCE model aims to expand access to GLP-1 medications for weight management in Medicare and Medicaid through negotiated pricing, launching May 2026.
CMS BALANCE Model Targets Rural Access Gaps for GLP-1 Weight Loss Drugs
New federal initiative pairs Medicare and Medicaid GLP-1 coverage with rural health investments, but voluntary participation raises questions about equitable access.
Stopping GLP-1 Drugs Rapidly Erases Heart Benefits, Major Study Finds
Large study of 333,000+ patients shows stopping GLP-1 medications can increase cardiovascular risk by 22% within two years, largely erasing years of heart protection benefits.